Literature DB >> 31910262

New Flu Antiviral Candidate May Thwart Drug Resistance.

Tracy Hampton.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 31910262     DOI： 10.1001/jama.2019.20225

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  9 in total

1.  Drugs that Might Be Possibly Used for Treatment of COVID-19 Patients.

Authors:  Mehdi Salih Shihab; Baram Hamah-Ameen
Journal:  Russ J Bioorg Chem       Date:  2021-08-21       Impact factor: 0.796

Review 2.  Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review.

Authors:  Rami A Al-Horani; Srabani Kar
Journal:  Viruses       Date:  2020-09-26       Impact factor: 5.048

Review 3.  Exploring the multifocal therapeutic approaches in COVID-19: A ray of hope.

Authors:  Arun Kumar; Asmita Deka Dey; Tapan Behl; Swati Chadha; Vishal Aggarwal
Journal:  Int Immunopharmacol       Date:  2020-11-03       Impact factor: 4.932

Review 4.  Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.

Authors:  Anna Artese; Valentina Svicher; Giosuè Costa; Romina Salpini; Velia Chiara Di Maio; Mohammad Alkhatib; Francesca Alessandra Ambrosio; Maria Mercedes Santoro; Yehuda G Assaraf; Stefano Alcaro; Francesca Ceccherini-Silberstein
Journal:  Drug Resist Updat       Date:  2020-08-26       Impact factor: 18.500

5.  Nanoparticle composite TPNT1 is effective against SARS-CoV-2 and influenza viruses.

Authors:  Sui-Yuan Chang; Kuo-Yen Huang; Tai-Ling Chao; Han-Chieh Kao; Yu-Hao Pang; Lin Lu; Chun-Lun Chiu; Hsin-Chang Huang; Ting-Jen Rachel Cheng; Jim-Min Fang; Pan-Chyr Yang
Journal:  Sci Rep       Date:  2021-04-22       Impact factor: 4.379

Review 6.  Molnupiravir and Its Antiviral Activity Against COVID-19.

Authors:  Lili Tian; Zehan Pang; Maochen Li; Fuxing Lou; Xiaoping An; Shaozhou Zhu; Lihua Song; Yigang Tong; Huahao Fan; Junfen Fan
Journal:  Front Immunol       Date:  2022-04-04       Impact factor: 7.561

7.  Authorization of COVID-19 clinical trials: lessons from 2 years of experience of a national competent authority.

Authors:  Stéphane Vignot; Alban Dhanani; Isabelle Sainte-Marie; Laure de Ligniville Lajavardi; Gwennaelle Even; Muriel Echemann; Nina Hulin; Claire Ménoret; Patrick Maison; Christelle Ratignier-Carbonneil
Journal:  Front Pharmacol       Date:  2022-08-15       Impact factor: 5.988

Review 8.  Systems Biology Approaches for Therapeutics Development Against COVID-19.

Authors:  Shweta Jaiswal; Mohit Kumar; Yogendra Singh; Pratyoosh Shukla
Journal:  Front Cell Infect Microbiol       Date:  2020-10-28       Impact factor: 5.293

Review 9.  Natural Photosensitizers in Antimicrobial Photodynamic Therapy.

Authors:  Ece Polat; Kyungsu Kang
Journal:  Biomedicines       Date:  2021-05-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.